中文

Hong Kong Stocks · Free Data Page

GRAND PHARMA 00512

GRAND PHARMA: FY2025 revenue HK$12.28B (+5.50% YoY); net income HK$1.24B; 1 alert, 3 watch items out of 17 risk checks; TTM dividend HK$0.17/sh.
Close PriceHK$4.29Day +0.94%Market CapHK$15.21BP/E13.7xTTMP/B0.88xDividend Yield3.89%TTMROE (FY2025)7.4%Avg. equity

Prices are closing data as of 2026-11-04, not real-time quotes. HK P/E and P/B multiples come from Eastmoney HK key statistics. Metric definitions: P/E, P/B, ROE.

Want the full AI research report for GRAND PHARMA?

This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.

New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.

10-Year FinancialsFY2016–2025

Key Multi-Year Facts

  • Revenue moved from HK$3.70B in FY2016 to HK$12.28B in FY2025 (9-year CAGR +14.3%).
  • Profitable in every fiscal year across 2016–2025.

Latest 5 Fiscal Years

Fiscal Year20212022202320242025
Revenue (HKD B)8.609.5610.511.612.3
YoY35.3%11.2%10.1%10.6%5.5%
Net Income (HKD B)2.402.081.882.471.24
YoY34.0%-13.4%-9.6%31.3%-49.7%
Operating Cash Flow (HKD B)1.641.652.201.761.49
ROE19.5%15.1%12.8%15.6%7.4%
Gross Margin61.0%62.2%62.0%57.9%55.2%
Net Margin27.9%21.7%17.9%21.2%10.1%
Debt-to-Assets36.2%36.5%32.2%33.9%37.5%
Show all 10 fiscal years
Fiscal Year2016201720182019202020212022202320242025
Revenue (HKD B)3.704.775.966.596.358.609.5610.511.612.3
YoY—29.1%24.9%10.6%-3.6%35.3%11.2%10.1%10.6%5.5%
Net Income (HKD B)0.270.460.711.151.792.402.081.882.471.24
YoY—71.2%54.7%61.5%55.8%34.0%-13.4%-9.6%31.3%-49.7%
Operating Cash Flow (HKD B)0.690.601.231.171.231.641.652.201.761.49
ROE15.8%23.4%15.1%14.8%18.3%19.5%15.1%12.8%15.6%7.4%
Gross Margin46.9%52.0%53.1%61.3%63.5%61.0%62.2%62.0%57.9%55.2%
Net Margin7.3%9.7%12.0%17.5%28.2%27.9%21.7%17.9%21.2%10.1%
Debt-to-Assets72.3%69.5%44.9%38.4%33.2%36.2%36.5%32.2%33.9%37.5%

Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: HKEX / Eastmoney financial statements, compiled mechanically without AI. Official filings

Risk ChecklistAs of 2026-11-05

Rules-based screening using HK financial statements and HKEX announcement categories (no AI opinions).

1Alert 3Watch 13Pass

Items Flagged for Review

  • Alert

    Short-Term Debt CoverageSolvency

    Cash HK$0.62B, short-term debt HK$1.67B (0.37x)

    Interim (2026-06-30) · What is this?

  • Watch

    GoodwillFinancial Quality

    HK$1.80B, 10.4% of equity

    Interim (2026-06-30) · What is this?

  • Watch

    Profit WarningMaterial Events

  • Watch

    Auditor ChangeMaterial Events

An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.

Dividends

Trailing 12-month dividend: HK$0.167 per share, or 3.89% yield at closing price; last full fiscal year: HK$0.167 (payout ratio 54.6%).

Figures are gross HKD per share before applicable withholding or Stock Connect dividend taxes.

More data: All research reports · Sector leaders · Market hours & holidays.

Compiled mechanically from public filings and market quotes (data as of 2026-11-05). For informational purposes only, not investment advice.